Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2024-02-13 Regulatory Filings
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the approval of a drug registration by a health authority (INVIMA) in Colombia for Avicenna's pharmaceutical product Trunerox. It focuses on regulatory approval and commercialization milestones rather than financial results, management changes, or shareholder information. There is no indication of financial statements, earnings data, or detailed management discussion. The content is typical of a regulatory or corporate announcement about product approval and market entry. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. Confidence is high given the clear nature of the announcement and absence of financial or governance content.
2024-02-13 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a supply and licensing agreement between Avicanna Inc. and a multinational pharmaceutical company. It details the nature of the agreement, the products involved, and the strategic intentions for market expansion. There is no financial data, regulatory filing, or detailed report content such as financial statements or management analysis. The document is an announcement of a business development or partnership rather than a financial report, regulatory filing, or management disclosure. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified under Capital/Financing Update (CAP) as it relates to a strategic commercial agreement impacting the company's business and potential revenue streams through licensing and supply agreements.
2024-02-05 English
News release - English.pdf
Regulatory Filings
2024-01-30 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings
2023-12-14 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2023-12-14 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Pricing Supplement No. 1,340' and references a 'Short Form Base Shelf Prospectus dated October 7, 2022.' It details the terms, conditions, and pricing of a specific issuance of structured notes by Canadian Imperial Bank of Commerce (CIBC). The content includes detailed descriptions of the notes, indices linked to the notes, pricing, issue size, dealers, and the calculation of returns. This type of document is a supplement to a prospectus and is used to provide specific offering details for a particular tranche of securities. It is not a financial report, earnings release, or regulatory filing in the sense of periodic financial disclosures. It is also not an announcement of a report publication but a primary offering document. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including new securities offerings and related prospectus supplements.
2023-12-04 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.